DOCSLIB.ORG

Dosulepin Mylan Contains the Active Ingredient Dosulepin (Dothiepin) Hydrochloride CONSUMER MEDICINE INFORMATION

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dosulepin Mylan Contains the Active Ingredient Dosulepin (Dothiepin) Hydrochloride CONSUMER MEDICINE INFORMATION Dosulepin Mylan contains the active ingredient dosulepin (dothiepin) hydrochloride CONSUMER MEDICINE INFORMATION What is in this leaflet Ask your doctor if you have any Dosulepin Mylan may increase the questions about why Dosulepin chance of fitting or having This leaflet answers some common Mylan has been prescribed for you. convulsions. questions about Dosulepin Mylan. Your doctor may have prescribed · recently had a heart attack, for It does not contain all the available Dosulepin Mylan for another reason. example within the past two information. It does not take the Dosulepin Mylan is not approved months place of talking to your doctor or for use in children and adolescents Dosulepin Mylan may cause irregular pharmacist. below 18 years of age for the and/or rapid heartbeat. All medicines have benefits and treatment of depression. · liver failure. risks. Your doctor has weighed the The safe use and effectiveness of Your body may not be able to risks of you taking Dosulepin Mylan Dosulepin Mylan in treating remove Dosulepin Mylan from your against the benefits expected for you. depression, for this age group, has body. not been established. If you have any concerns about Do not take Dosulepin Mylan if taking this medicine, talk to your Dosulepin Mylan is available only you are taking a medicine called a doctor or pharmacist. with a doctor©s prescription. monoamine oxidase inhibitor Please read this leaflet carefully (MAOI), or have taken a MAOI and keep it with your medicine. within the last 14 days. You may need to read it again. Stop taking MAOIs at least 14 days Before you take before starting Dosulepin Mylan. Dosulepin Mylan Taking Dosulepin Mylan with a MAOI may cause a serious reaction When you must not take it What Dosulepin Mylan with a sudden increase in body is used for Do not take Dosulepin Mylan if temperature, extremely high blood you are allergic to medicines pressure and severe convulsions. Dosulepin Mylan is used to treat containing dothiepin (e.g. Ask your doctor or pharmacist if depression. Prothiaden) or any of the you are not sure if you have been Dosulepin Mylan 25 mg capsules can ingredients listed at the end of this taking a MAOI medicine. be used at any stage in the treatment leaflet. MAOIs are medicines used to treat of depression. However, the higher Some of the symptoms of an allergic depression and symptoms of strength Dosulepin Mylan 75 mg reaction may include Parkinson©s disease, such as tablets are approved only for the · shortness of breath phenelzine (Nardil), tranylcypromine maintenance treatment of depression (Parnate), moclobemide (eg. Aurorix (after your symptoms have · wheezing or difficulty breathing Arima) and selegiline (Eldepryl, improved). · swelling of the face, lips, tongue Selgene). Dosulepin Mylan belongs to a group or other parts of the body Do not take Dosulepin Mylan if the of medicines called tricyclic · rash, itching or hives on the skin expiry date (EXP.) printed on the antidepressants (TCAs). TCA · discolouration of the skin upon pack has passed. medicines work by correcting the exposure to sunlight imbalance of certain chemicals in the If you take this medicine after the brain. These chemicals, called expiry date has passed, it may not amines, are involved in controlling Do not take Dosulepin Mylan if work as well. mood. By correcting this imbalance, you have: Do not take Dosulepin Mylan if the TCAs can help relieve the symptoms · epilepsy packaging shows signs of of depression. DOSULEPIN MYLAN 1 tampering or the tablets or If you have not told your doctor Your doctor and pharmacist have capsules do not look quite right. about any of the above, tell them more information on medicines to be If you are not sure whether you before you start taking Dosulepin careful with or avoid while taking should start taking this medicine, Mylan. Dosulepin Mylan. talk to your doctor. Taking other medicines Before you start to take it Do not take Dosulepin Mylan if you are taking a monoamine How to take Dosulepin Tell your doctor if you are allergic Mylan to any other medicines, foods, dyes oxidase inhibitor (MAOI) such as: · phenelzine (Nardil) and or preservatives. Follow all directions given to you tranylcypromine (Parnate), Tell your doctor if you are by your doctor and pharmacist moclobemide (eg. Aurorix, pregnant or plan to become carefully. Arima), used to treat depression pregnant. They may differ from the · selegiline (Eldepryl, Selgene), There have been reports of some information contained in this leaflet. babies experiencing complications used to treat symptoms of If you do not understand the immediately after delivery. Your Parkinson©s disease. instructions on the pack, ask your doctor will discuss the possible risks Wait at least 14 days after stopping doctor or pharmacist. and benefits of taking Dosulepin your MAOI before starting Mylan during pregnancy. Dosulepin Mylan. How much to take Tell your doctor if you are Tell your doctor if you are taking The dose varies from person to breastfeeding or wish to any other medicines, including any person. breastfeed. that you buy without a Your doctor will tell you how much Like many other medicines, prescription from a pharmacy, Dosulepin Mylan you need to take Dosulepin Mylan passes into breast supermarket or health food shop. each day and when to take it. This milk. Medicines that may be affected by depends how well you respond to Dosulepin Mylan or may affect how Your doctor will discuss the risks and Dosulepin Mylan and whether or not well it works include: benefits of taking Dosulepin Mylan you are taking any other medicines. when breastfeeding. · sleeping tablets/sedatives, anti- The usual starting dose is 25 mg anxiety medicines Tell your doctor if you have, or three times daily for one to two have had, any medical conditions, · medicines used to treat epilepsy weeks. Your doctor may then especially the following: · some medicines used to treat high increase your dose, up to a maximum · heart or blood vessel problems blood pressure or other heart of 200 mg per day. · liver problems or hepatitis conditions Once your symptoms improve, your · kidney problems or difficulty · some medicines used to relieve doctor will then slowly reduce your passing urine (water) stomach cramps dose to the lowest effective dose which maintains relief of symptoms. · glaucoma, a condition · medicines used to treat characterised by an increased Parkinson©s disease Elderly people over 65 years of age pressure in the eye · medicines for travel sickness and those with liver or kidney problems may need smaller doses. · prostate problems · some cough and cold preparations · difficulty in passing urine · some medicines for hayfever and How to take it allergies · thyroid problems Swallow the tablets or capsules · any other mental illness, such as · certain medicines for weight loss with a glass of water. schizophrenia or manic · thyroid hormone medicines. The 75 mg tablets can be divided in depression (alternating periods of Your doctor can tell you what to do if half along the breakline if advised by elation/overactivity and depressed you are taking any of these your doctor or pharmacist. mood) medicines. When to take it · family history of suicide or manic If you are not sure whether you are depression. taking any of these medicines, Dosulepin Mylan can be taken as a Tell your doctor if you plan to have check with your doctor or single dose (e.g. at bedtime) or as surgery or if you are undergoing pharmacist. divided doses (e.g. three times a electroshock therapy. day). Your doctor will advise you. DOSULEPIN MYLAN 2 Take your medicine at about the If you have trouble remembering likely to occur in young adults under same time each day. to take your medicine, ask your 25 years of age. Taking it at the same time each day pharmacist for some hints. Contact your doctor or a mental will have the best effect. It will also health professional right away or help you remember when to take it. If you take too much go to the nearest hospital for (overdose) treatment if you or someone you How long to take it for Immediately telephone your know is showing any of the following warning signs of suicide: Keep taking Dosulepin Mylan for doctor, or the Poisons Information as long as your doctor Centre (telephone 13 11 26) for · worsening of your depression recommends. advice, or go to Accident and · thoughts or talk of death or Emergency at the nearest hospital, The length of treatment will depend suicide if you think you or anyone else on how quickly your symptoms may have taken too much · thoughts or talk of self-harm or improve. Dosulepin Mylan. harm to others Most medicines for depression take Do this even if there are no signs of · any recent attempts of self-harm time to work, so do not be discomfort or poisoning. · increase in aggressive behaviour, discouraged if you do not feel better irritability or any other unusual right away. Some of your symptoms You may need urgent medical changes in behaviour or mood. may improve in 1 or 2 weeks but it attention. can take up to 4 or 6 weeks to feel Too much Dosulepin Mylan may All mentions of suicide or violence the full benefit of Dosulepin Mylan. make you tremble, agitated and/or must be taken seriously. Even when you feel well, you will have difficulty walking. Other signs Families and caregivers of children usually have to take Dosulepin include fitting or convulsions, and adolescents being treated with Mylan for several months or longer, unusual muscle movements, Dosulepin Mylan need to monitor to make sure that the benefits last. difficulty breathing, a very high these patients for the emergence temperature or irregular heartbeat as of: If you forget to take it well as other serious heart problems.
Load more

Recommended publications
  • Dosulepin Prescribing
    SAFETY BULLETIN: DOSULEPIN PRESCRIBING In December 2007, the Medicines and Healthcare Regulatory Agency (MHRA) issued safety advice around prescribing of dosulepin, related to the narrow margin between therapeutic doses and potentially fatal doses. Nevertheless, dosulepin continues to be prescribed widely. Over eight years after the safety advice was published, prescribing of dosulepin in the Dorset area remains high. In the South West area, Dorset CCG was the highest prescriber of dosulepin for the 2015/16 financial year (3.238% of all antidepressant items). Of the 209 CCGs in the UK, Dorset is the fourteenth highest prescriber of dosulepin, and well above the national average of 2.111%. The following points summarise the reasons that dosulepin is not recommended for prescribing nationally, and in Dorset: Dosulepin has a small margin of safety between the (maximum) therapeutic dose and potentially fatal doses. The NICE guideline on depression in adults recommends that dosulepin should not be prescribed for adults with depression because evidence supporting its tolerability relative to other antidepressants is outweighed by the increased cardiac risk and toxicity in overdose. Dosulepin has also been used ‘off label’ in other indications such as fibromyalgia and neuropathic pain. However the evidence for use in in this way is weak, and is not recommended. The lethal dose of dosulepin is relatively low and can be potentiated by alcohol and other CNS depressants. Dosulepin overdose is associated with high mortality and can occur rapidly, even before hospital treatment can be received. Onset of toxicity occurs within 4-6 hours. Every year, up to 200 people in England and Wales fatally overdose with dosulepin.
    [Show full text]
  • Dose Equivalents of Antidepressants Evidence-Based Recommendations
    Journal of Affective Disorders 180 (2015) 179–184 Contents lists available at ScienceDirect Journal of Affective Disorders journal homepage: www.elsevier.com/locate/jad Research report Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials Yu Hayasaka a,n, Marianna Purgato b, Laura R Magni c, Yusuke Ogawa a, Nozomi Takeshima a, Andrea Cipriani b,d, Corrado Barbui b, Stefan Leucht e, Toshi A Furukawa a a Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo- ku, Kyoto 606-8501, Japan b Department of Public Health and Community Medicine, Section of Psychiatry, University of Verona, Policlinico “G.B.Rossi”, Pzz.le L.A. Scuro, 10, Verona 37134, Italy c Psychiatric Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy d Department of Psychiatry, University of Oxford, Oxford, UK e Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany article info abstract Article history: Background: Dose equivalence of antidepressants is critically important for clinical practice and for Received 4 February 2015 research. There are several methods to define and calculate dose equivalence but for antidepressants, Received in revised form only daily defined dose and consensus methods have been applied to date. The purpose of the present 10 March 2015 study is to examine dose equivalence of antidepressants by a less arbitrary and more systematic method. Accepted 12 March 2015 Methods: We used data from all randomized, double-blind, flexible-dose trials comparing fluoxetine or Available online 31 March 2015 paroxetine as standard drugs with any other active antidepressants as monotherapy in the acute phase Keywords: treatment of unipolar depression.
    [Show full text]
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Efficacy of Dosulepin in Tension Type Headache and Midfacial Pain a Randomised Controlled Study
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 19, Issue 3 Ser.4 (March. 2020), PP 10-14 www.iosrjournals.org Efficacy of Dosulepin in Tension Type Headache and Midfacial Pain a Randomised Controlled Study Corresponding Author: XXXXX Abstract Introduction: Patients presenting with pain in the facial region are commonly reffered to Otorhinolaryngologist. Due to the various causative factors causing pain in the facial region, the proper diagnosis and more importantly the skill to rule out the sinogenic pain plays an important role in management. Tension type headache and midfacial pain are often misdiagnosed and treated wrongly and thus add to the morbidity of patients. Of all the medications that are used for the treatment, most provide minimal, short term relief with side effects on prolong use. Dosulepin a Tricyclic Antidepressant helps in relieving pain with minimal side effects as compared to other Tricyclic Antidepressants. Aims and Objective: To study the efficacy of dosulepin in patients attending outpatient Department of otorhinolaryngology of Silchar Medical College and Hospital Methods: 130 patients attending outpatient Department of ENT and Head and Neck Surgery of Silchar Medical College & Hospital, from September 2017 to August 2018 with complaints of headache diagnosed as tension type headache and midfacial pain were evaluated. Neurological and radiographic examinations were performed prior to therapy and local cause of pain in the facial region were ruled out. Together with this we also performed psychic evaluation for those patients who could not be withdrawn from current medication and then to start them on our current medication.
    [Show full text]
  • Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW
    Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW Name of Medicine / Trimipramine (Surmontil®) Class (generic and brand) Licensed indication(s) Treatment of depressive illness, especially where sleep disturbance, anxiety or agitation are presenting symptoms. Sleep disturbance is controlled within 24 hours and true antidepressant action follows within 7 to 10 days. Licensed dose(s) Adults: For depression 50-75 mg/day initially increasing to 150-300 mg/day in divided doses or one dose at night. The maintenance dose is 75-150 mg/day. Elderly: 10-25 mg three times a day initially. The initial dose should be increased with caution under close supervision. Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response. Children: Not recommended. Purpose of Document To review information currently available on this class of medicines, give guidance on potential use and assign a prescribing classification http://www.cambsphn.nhs.uk/CJPG/CurrentDrugClassificationTable.aspx Annual cost (FP10) 10mg three times daily: £6,991 25mg three times daily: £7,819 150mg daily: £7,410 300mg daily: £14,820 Alternative Treatment Options within Class Tricyclic Annual Cost CPCCG Formulary Classification Antidepressant (FP10) Amitriptyline (75mg) Formulary £36 Lofepramine (140mg) Formulary £146 Imipramine (75mg) Non-formulary £37 Clomipramine (75mg) Non-formulary £63 Trimipramine (75mg). TBC £7,819 Nortriptyline (75mg) Not Recommended (pain) £276 Doxepin (150mg) TBC £6,006 Dosulepin (75mg) Not Recommended (NICE DO NOT DO) £19 Dosages are based on possible maintenance dose and are not equivalent between medications Recommendation It is recommended to Cambridgeshire and Peterborough CCG JPG members and through them to local NHS organisations that the arrangements for use of trimipramine are in line with restrictions agreed locally for drugs designated as NOT RECOMMENDED:.
    [Show full text]
  • Detecting Depression and Anxiety in Older Adults
    Detecting Depression and Anxiety in Older Adults Dr Nick Woodthorpe Depression in Older Adults Introduction to Depression • 1 in 5 older people living in the community • 2 in 5 living in care homes Causes of Depression • Painful events • Past depression or family history • Personality • Physical illness • Medicines • Drugs and Alcohol • Loneliness Particular Issues in Depression • Physical symptoms, for example, thyroid problems, heart disease or arthritis. • Long-term illness • Confusion and memory problems • A new sense of loneliness/lack of purpose Depression - Symptoms • 2 weeks • No hypomania or mania • No psychoactive drugs • No organic mental disorder Depression - Symptoms • Feeling low or sad (they may not report this) • Loss of interest in life • Low energy and tired for no reason Depression - Symptoms • Change in appetite and weight • Restlessness or psychomotor retardation • Anxious • Avoidance • Irritable • Sleep disturbance • Loss of confidence and self-esteem Depression - Symptoms • Hopelessness and worthlessness • Poor concentration • Panicky • Loss of libido • Sense of guilt • Suicidal thoughts • Delusions or hallucinations Depression - Diagnostic Categories • Mild • Moderate • Severe with or without psychosis • Recurrent Anxiety in Later Life Everyone gets anxious sometimes Everyone gets anxious sometimes Fight or Flight Response Fight or Flight Response Causes of anxiety in later life • Painful events • Stress • Past experiences- upbringing/Childhood • Personality • Physical illness • Medicines • Diet - caffeine, excess
    [Show full text]
  • Prescribing Newsletter
    Prescribing Newsletter Produced by Herefordshire CCG Medicines Optimisation Team December 2013 Newer Oral Anticoagulants (NOACs) STOP PRESS! Key Points: 1. Adherence: not suitable for patients with poor adherence. Urgent Calls Community pharmacists will target patients prescribed anti- The festive season coagulants for the New Medicines Service (NMS) and workload is upon us which makes annual Medicines Use Review (MUR). it even more important to ensure 2. Patient information & alert cards: vital for all patients, effective communication between including advice on bleeding risk and action to take in the health professionals to avoid patient safety incidents. event of bleeding. Obtain from pharmaceutical companies. 3. Check renal function: dose reduction may be required. Practices are asked to review 4. Monitoring: baseline and annual (minimum) U&Es. systems to ensure front line staff are aware of the need for prompt Annual review by GP and pharmacist to reinforce connection to prescribers to solve importance of adherence to treatment and check for ADRs. medicines queries to reduce Rivaroxaban in DVT Treatment delays for patients and carers save Patients experiencing DVT now have a new treatment option in time for both clinical and admin line with NICE TA261: staff. Rivaroxaban 15mg BD x 21 days, followed by 20mg OD Examples include alternatives to Guidelines for the safe use of rivaroxaban in DVT are available out of stock medicines, palliative on the intranet. care queries, medicine overuse GPs suspecting a DVT diagnosis will be likely to offer oral concerns and medicine queries rivaroxaban instead of LMWH injections (enoxaparin) for most from hospital staff relating to patients.
    [Show full text]
  • Still the Leading Antidepressant After 40 Years of Randomised Controlle
    BRITISH JOURNAL OF PSYCHIATRY "2001), 178, 129^144 REVIEW ARTICLE Amitriptyline vv.therest:stilltheleading METHOD Inclusion criteria antidepressant after 40 years of randomised All RCTs comparing amitriptyline with any y other tricyclic,heterocyclic or SSRI were in- controlled trials cluded. Crossover studies were excluded. Studies adopting any criteria to define CORRADO BARBUI and MATTHEW HOTOPF patients suffering from depression were included; a concurrent diagnosis of another psychiatric disorder was not considered an exclusion criterion. Trials in patients with depression with a concomitant medical ill- Background Tricyclic antidepressants Amitriptyline is one of the first `reference' ness were not included in this review. have similar efficacy and slightly lower tricyclic antidepressants TCAs). Over the past 40 years a number of newer tricyclics, tolerability than selective serotonin Search strategy heterocyclics and selective serotonin re- Relevant studies were located by searching reuptakeinhibitorsreuptake inhibitors SSRIs).However, uptake inhibitors SSRIs) have been intro- the Cochrane Collaboration Depression, there are no systematic reviews assessing duced Garattini et aletal,1998). Despite Anxiety and Neurosis Controlled Trials several large systematic reviews comparing amitriptyline, the reference tricyclic drug, Register CCDANCTR). This specialised tricyclics and SSRIs there is no clear agree- vv. other tricyclics and SSRIs directly. register is regularly updated by electronic ment over first-line treatment of depression Medline,Embase,PsycINFO,LILACS, SongSong et aletal,1993; Anderson & Tomenson, Aims ToreviewTo review the tolerability and Psyndex,CINAHL,SIGLE) and non-electro- 1995; Montgomery & Kasper,1995; efficacy of amitriptyline inthe nicnicliterature searches. The register was HotopfHotopf et aletal,1996; Canadian Coordinating management of depression. searched using the following terms: Office for Health Technology Assessment, AMITRIPTYLIN**AMITRIPTYLIN oror AMITRILAMITRIL oror ELA-ELA- 19971997aa).
    [Show full text]
  • Association of Selective Serotonin Reuptake Inhibitors with the Risk for Spontaneous Intracranial Hemorrhage
    Supplementary Online Content Renoux C, Vahey S, Dell’Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published online December 5, 2016. doi:10.1001/jamaneurol.2016.4529 eMethods 1. List of Antidepressants for Cohort Entry eMethods 2. List of Antidepressants According to the Degree of Serotonin Reuptake Inhibition eMethods 3. Potential Confounding Variables Included in Multivariate Models eMethods 4. Sensitivity Analyses eFigure. Flowchart of Incident Antidepressant (AD) Cohort Definition and Case- Control Selection eTable 1. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 2. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 3. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs. eTable 4. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 5. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 6. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 eMethods 1.
    [Show full text]
  • Package Leaflet: Information for the User
    Package leaflet: Information for the use Linezolid [MAH] 2 mg/ml solution for infusion Linezolid Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Linezolid [MAH] is and what it is used for 2. What you need to know before you use Linezolid [MAH] 3. How to use Linezolid [MAH] 4. Possible side effects 5. How to store Linezolid [MAH] 6. Contents of the pack and other information 1. What Linezolid [MAH] is and what it is used for Linezolid [MAH] is an antibiotic of the oxazolidinones group that works by stopping the growth of certain bacteria (germs) that cause infections. It is used to treat pneumonia and some infections in the skin or under the skin. Your doctor will have decided if Linezolid [MAH] is suitable to treat your infection. 2. What you need to know before you use Linezolid [MAH] You should not be treated with Linezolid [MAH]: if you are allergic (hypersensitive) to linezolid or any of the other ingredients of this medicine if you are taking or have taken within the last 2 weeks any medicines known as monoamine oxidase inhibitors (MAOIs: for example phenelzine, isocarboxazid, selegiline, moclobemide). These medications may be used to treat depression or Parkinson’s disease; if you are breastfeeding.
    [Show full text]
  • Tcas Versus Placebo - New Studies in the Guideline Update
    TCAs versus placebo - new studies in the guideline update Comparisons Included in this Clinical Question Amitriptyline vs placebo Clomipramine vs placebo Dosulepin (dothiepin) vs placebo AMSTERDAM2003A LARSEN1989 FERGUSON1994B BAKISH1992B PECKNOLD1976B ITIL1993 BAKISH1992C RAMPELLO1991 MINDHAM1991 BREMNER1995 THOMPSON2001B CLAGHORN1983 CLAGHORN1983B FEIGHNER1979 GELENBERG1990 GEORGOTAS1982A GOLDBERG1980 HICKS1988 HOLLYMAN1988 HORMAZABAL1985 HOSCHL1989 KLIESER1988 LAAKMAN1995 LAPIERRE1991 LYDIARD1997 MYNORSWALLIS1995 MYNORSWALLIS1997 REIMHERR1990 RICKELS1982D RICKELS1985 RICKELS1991 ROFFMAN1982 ROWAN1982 SMITH1990 SPRING1992 STASSEN1993 WILCOX1994 16 Imipramine vs placebo BARGESCHAAPVELD2002 BEASLEY1991B BOYER1996A BYERLEY1988 CASSANO1986 CASSANO1996 CLAGHORN1996A COHN1984 COHN1985 COHN1990A COHN1992 COHN1996 DOMINGUEZ1981 DOMINGUEZ1985 DUNBAR1991 ELKIN1989 ENTSUAH1994 ESCOBAR1980 FABRE1980 FABRE1992 FABRE1996 FEIGER1996A FEIGHNER1980 FEIGHNER1982 FEIGHNER1983A FEIGHNER1983B FEIGHNER1989 FEIGHNER1989A FEIGHNER1989B FEIGHNER1989C FEIGHNER1992B FEIGHNER1993 FONTAINE1994 GELENBERG2002 GERNER1980B HAYES1983 ITIL1983A KASPER1995B KELLAMS1979 LAIRD1993 LAPIERRE1987 LECRUBIER1997B LIPMAN1986 LYDIARD1989 MARCH1990 17 MARKOWITZ1985 MENDELS1986 MERIDETH1983 Nortriptyline vs placebo NANDI1976 GEORGOTAS1986A NORTON1984 KATZ1990 PEDERSEN2002 NAIR1995 PESELOW1989 WHITE1984A PESELOW1989B PHILIPP1999 QUITKIN1989 RICKELS1981 RICKELS1982A RICKELS1987 SCHWEIZER1994 SCHWEIZER1998 SHRIVASTAVA1992 SILVERSTONE1994 SMALL1981 UCHA1990 VERSIANI1989 VERSIANI1990
    [Show full text]
  • Print This Article
    International Journal of Advances in Medicine Kumar MS et al. Int J Adv Med. 2021 Oct;8(10):1551-1559 http://www.ijmedicine.com pISSN 2349-3925 | eISSN 2349-3933 DOI: https://dx.doi.org/10.18203/2349-3933.ijam20213642 Original Research Article Effectiveness and tolerability of eight-week treatment with dosulepin hydrochloride in patients with major depressive disorder not responding to four consecutive weeks of treatment with single selective serotonin reuptake inhibitor M. Suresh Kumar1*, Amrit Pattojoshi2 1PSYMED Hospital, Harrington Road, Shenoy Nagar, Chennai, Tamil Nadu, India 2Dr. Amrit Pattojoshi's Clinic, Bhouma Nagar, Bhubaneswar, Odisha, India Received: 12 August 2021 Accepted: 23 August 2021 *Correspondence: Dr. M. Suresh Kumar, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Though manageable, major depressive disorder remains an underdiagnosed and undertreated condition. The objective of this study was to assess the effectiveness and safety of 8 weeks of treatment with the tricyclic antidepressant dosulepin hydrochloride in patients with depressive episodes not responsive to 4 consecutive weeks of treatment with a single selective serotonin reuptake inhibitor (SSRI). Methods: Patients diagnosed with depressive episode without psychotic symptoms (by ICD-10 diagnostic criteria for research), mini-mental state examination score of ≥24, and not responsive to four weeks of treatment with SSRIs (<50% reduction in depressive symptoms) were enrolled. The main outcome measures were mean change in the Hamilton depression, Hamilton anxiety, and insomnia severity index scores at Week 8 compared to baseline.
    [Show full text]